Post-Election Day Tests Linger for Healthcare ETFs

Related: ETF Plays for a Divided Midterm Elections

A divided Congress would also mean real immediate regulatory changes on price changes in the pharmaceutical industry.

“While most polls are pointing to the Democrats gaining control of the House and Republicans keeping the Senate, if the Democrats gain control of both houses, pharmaceutical companies might come under even greater pressure, some ETF experts say,” reports the Journal. “That’s because with the Democrats in control, pushes to allow importation of cheaper medicines from other countries, make generic drugs more broadly available and require manufacturers to publicly justify their price levels could gain momentum.”

For more information on the healthcare segment, visit our healthcare category.